Gri bio reports full year 2023 financial results and provides corporate update

Ongoing phase 2a biomarker study evaluating lead program gri-0621 for the treatment of idiopathic pulmonary fibrosis (ipf) with interim data expected h1 2024 and topline data expected h2 2024

GRI Ratings Summary

GRI Quant Ranking